tbuckley/cabot-search huggingface dataset:
Mammography-detected breast cancer among 40-49-year-old patients at a community-based cancer center: 1990-2008.
Authors: J. A. Malmgren, M. K. Atwood, H. G. Kaplan
Journal: Journal of Clinical Oncology (2010)

1605 Background: A recent update of the 2002 US Preventive Services Task Force recommends against routine mammography screening for 40-49 year olds based on efficacy evidence of screening modalities to reduce mortality. Methods: We conducted a prospective cohort study of all women presenting with primary breast cancer, aged 40-49, biopsy confirmed stage 0-IV from 1990-2008 identified and tracked by our registry. Clinical presentation characteristics including age, race, TNM stage, family and pregnancy history, histologic type and method of detection by patient (PtD), physician (PhysD) or mammography (MgD) were chart abstracted at time of diagnosis. Cases with unknown or other method of detection (n = 29) were removed (n = 1,974). Results: Among women 40-49 years of age we noted a significant increase in MgD breast cancer from 1990-2008 (28% to 58%) and a concurrent decline in PtD breast cancer (63% to 36%) (Pearson Chi-Square = 72.72, p < 0.001). Percentage PhysD breast cancer remained steady. Among MgD breast cancer, stage 0 breast cancer cases increased over time from approximately 20% to an average of 41% for years 2003-2008. Overall 95% of MgD breast cancers were stage 0-II vs. 75% of PtD breast cancers and 76% of PhysD (Pearson Chi-Square = 406.55, p < 0.001). Histologic type differed significantly between the MgD and the PtD breast cancers with 22% DCIS among MgD vs. 3% of PtD, and 62% ductal among MgD vs. 78% of PtD. Three times as many women died of disease among PtD breast cancer patients compared to MgD breast cancer patients (10.4% [n = 102] vs. 3.6% [n = 31]) (Pearson Chi-Square = 34.51, p < 0.001). Conclusions: A significant increase in mammography detected breast cancer was observed over time at our institution with an increase in lower TNM stage breast cancer and DCIS. A lower rate of disease-related mortality was observed among mammography detected breast cancer patients. The proportion of DCIS in the MgD group is roughly equivalent to the difference between the higher ductal cancer incidence among PtD breast cancers compared to MgD breast cancer. If routine mammography screening in 40-49 year olds is discontinued, the MgD DCIS cancers may present later as PtD ductal breast cancer at a higher stage. No significant financial relationships to disclose.
US doctors recommend continuous glucose monitoring for patients with type 1 diabetes
Authors: Michael McCarthy
Journal: BMJ (2016)

Adult patients with type 1 diabetes should use continuous glucose monitoring (CGM) devices to manage their blood glucose levels, the Endocrine Society has recommended in new guidelines.1

The recommendations, which were published in the society’s Journal of Clinical Endocrinology and Metabolism , were supported by the European Society of Endocrinology.

CGM devices, which use subcutaneous sensors to monitor blood glucose concentration, let patients track their blood glucose levels in near real time and adjust their insulin doses accordingly. The devices usually have alarms that warn patients when their blood glucose falls too low or rises …
Sixty seconds on . . . medical philanthropists
Authors: Anne Gulland
Journal: BMJ (2016)

No, the Microsoft founder and scourge of infectious diseases, Bill Gates, has a rival to the title of saviour of the world. Mark Zuckerberg, the man behind Facebook, and his wife, Priscilla Chan, have pledged £2.3bn ($3bn; €2.7bn) over the next decade to “cure, manage, and prevent all diseases within our children’s lifetime.”

Zuckerberg says that scientists have told him that his aim is not only …
Comprehensive cost of treating one patient with MDR/pre-XDR-TB in Wellington, New Zealand
Authors: Amanda McNaughton, Timothy Blackmore, Harry McNaughton
Journal: European Respiratory Journal (2016)

Diel and co-workers [1, 2] have reported the estimated cost of treating tuberculosis (TB) and multidrug-resistant (MDR)-TB in Germany and the European Union, which, along with estimated and modelling cost data from the USA, Asia and South Africa [3, 4], confirm the huge economic burden to range between 40 and 200 times higher than treating fully sensitive TB cases. We describe the full costs of treatment of a person who was treated in 2014–2015 in Wellington, New Zealand. He had MDR-TB plus ofloxacin resistance but marginal moxifloxacin susceptibility ( i.e. MDR/pre-extensively drug-resistant (XDR)-TB). This case highlights the key drivers of cost in a high-income country. € 200 000: the full cost of treating a single MDR/pre-XDR-TB patient in New Zealand <http://ow.ly/NkGT301B5KN>
The FLAG Chemotherapy Regimen Is an Alternative to Anthracycline Based Therapy for the Treatment of Acute Myeloid Leukemia for Patients with Multiple Co-Morbidities or Preexisting Cardiac Disease
Authors: Lalit Saini, Robert Turner, Loree Larratt, Joseph Brandwein, Marlene Ann Hamilton, Anthea Peters, Cynthia M. Wu, Nancy Zhu, Jeffery M. Patterson, Lauren Bolster, Michael Mant, Bruce Ritchie, Elena Liew, Imran Mirza, Graeme R. Quest, Sunita Gosh, Irwindeep Sandhu
Journal: Blood (2014)
BCL11B Mutations In T-Cell Acute Lymphoblastic Leukemia
Authors: Kim De Keersmaecker, Pedro Jose Real, Giusy Della Gatta, Teresa Palomero, Maria Luisa Sulis, Valeria Tosello, Pieter Van Vlierberghe, Kelly Barnes, Mireia Castillo, Xavier Sole, Michael Hadler, Jack Lenz, Peter Aplan, Michelle Kelliher, Barbara L. Kee, Pier Paolo Pandolfi, Dietmar Kappes, Fotini Gounari, Howard Petrie, Joni Van der Meulen, Frank Speleman, Elisabeth Paietta, Janis Racevskis, Martin Tallman, Jacob M. Rowe, Jean Soulier, David Avran, Hélène Cavé, Nicole Dastugue, Susana C. Raimondi, Jules Meijerink, Carlos Cordon-Cardo, Andrea Califano, Adolfo Ferrando
Journal: Blood (2010)
TP53 Mutation Profile and New Mutations in Chronic Lymphocytic Leukemia in Normandy
Authors: Nordine Lahyane, Julien Alani, Xavier Troussard, Stephane Cheze, Jean-Pierre Vilque, Seyeffedine Kadi, Vincent Launay, Edouard Cornet, Dina Istasi
Journal: Blood (2011)
Effect of Tenecteplase versus Alteplase on Platelets in Patients during the First Three Hours after Acute Myocardial Infarction (the ASSENT-2 Platelet Substudy)
Authors: VL Serebruany, AI Malinin, KP Callahan, AS Binbreck, Frans Van de Werf, JH Alexander, CB Granger, PA Gurbel
Journal: Circulation (2001)
Risk assessment in non-Ashkenazi women attending a cancer risk assessment clinic
Authors: S. V. Blank, J. A. Smith, K. J. Carapetyan, M. A. Utate, F. M. Muggia, J. P. Curtin
Journal: Journal of Clinical Oncology (2004)

6127 Background: Our Women's Cancer Screening and Prevention Project, a multidisciplinary cancer risk assessment clinic, was launched in April 2001. Our objective was to determine the demand for a women's cancer early detection and prevention program in a public metropolitan hospital serving immigrant women. Methods: Patient recruitment was accomplished via outreach strategies targeting community organizations and inreach programs within the institution. Patients visiting the clinic were seen by both gynecologic and medical oncologists, and underwent in-depth interviews, physical examinations and discussion of risk profiles. Risk categories were assigned for each woman using our IRB-approved questionnaire, mutation probability models, and discussion of each case at our weekly medical meeting. Recommendations were made concerning genetic counseling and testing, surveillance, risk reduction strategies and available clinical trials. Results: Among the 163 patients who have attended our clinic, 150 (92%) are not Ashkenazi. Our patients are Latina (43%), Caucasian (29%), African-American (19%) and Asian (8%). The median age of patients seen was 39, (range 20 - 76). 30% of our patients were classified as high risk (greater than 15% chance of harboring a deleterious BRCA 1 or 2 mutation), and surveillance and risk reduction recommendations were commensurate with this assessment. These high risk patients included 23 Latinas, 10 Asians and 7 African Americans. Results of genetic counseling and testing are pending at this time. Conclusions: The role and potential impact or breast and ovarian cancer risk assessment in populations not commonly associated with hereditary breast and ovarian cancers deserves further attention. Supported by the Lynne Cohen Foundation for Ovarian Cancer Research. No significant financial relationships to disclose.
A Practical Prediction Model for Overall Survival from Stage III Lung Cancer: a first step towards dose individualization
Authors: Cary Oberije, Ruud Houben, Dirk De Ruysscher, Anne-Marie C Dingemans, Gerben Bootsma, Wiel Geraedts, R Lunde, Cordula Pitz, Philippe Lambin
Journal: Journal of Thoracic Oncology (2011)
SPIROMICS Protocol for Multicenter Quantitative Computed Tomography to Phenotype the Lungs
Authors: Jered P. Sieren, John D. Newell, R. Graham Barr, Eugene R. Bleecker, Nathan Burnette, Elizabeth E. Carretta, David Couper, Jonathan Goldin, Junfeng Guo, MeiLan K. Han, Nadia N. Hansel, Richard E. Kanner, Ella A. Kazerooni, Fernando J. Martinez, Stephen Rennard, Prescott G. Woodruff, Eric A. Hoffman
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Section:ChooseTop of pageAbstract <<Implementation of Lung Im...Evidence of Successful St...DiscussionConclusionsReferencesCITING ARTICLES
A Dutch nationwide survivorship care program for Hodgkin lymphoma survivors.
Authors: Flora Van Leeuwen, Mars van 't Veer, Berthe M.P. Aleman, Nicky Dekker, John M. M. Raemaekers
Journal: Journal of Clinical Oncology (2016)

6 Background: Survivors of Hodgkin lymphoma (HL) are at increased risk of various late adverse effects of treatment, leading to substantial excess morbidity and mortality. Long-term follow-up care programs have been established for childhood cancer survivors, but not yet for HL survivors. The Dutch BETER consortium (Better care after Hodgkin lymphoma: Evaluation of long-term Treatment Effects and screening Recommendations) has developed a nationwide infrastructure for Survivorship Care Clinics for HL survivors. The consortium aims to: 1) establish follow-up guidelines for survivors; 2) identify survivors eligible for follow-up care; 3) educate survivors about late adverse treatment effects; and 4) provide risk-based care. Methods: Evidence-based follow-up guidelines were developed according to international standards. The guideline development group consisted of clinicians, methodological experts and patient representatives. To be eligible for follow-up care patients must have survived ≥ 5 yrs and have been treated at ages 15-70 years after 1969. Survivors were identified through the Netherlands Cancer Registry and hospital-based registries. Tracing of current addresses was done through the nationwide database of Municipal Offices. Results: We developed guidelines forsecond malignancies, cardiovascular disease, thyroid disease, osteoporosis and functional asplenia infection prophylaxis. Recommendations are given for fertility care and therapy for neck muscle weakness. We have identified and traced a cohort of 12,000 HL survivors in 23 centers, covering about 80% of HL patients in the Netherlands, of whom 8,500 appear to be eligible for follow-up care. For all survivors, treatment data were collected from the medical records to provide risk-based screening recommendations. A website and a survivorship care plan were developed to educate survivors about late effects. A nationwide database, including screening and adverse events data, is in development to evaluate the follow-up guidelines for diagnostic value and efficacy. Conclusions: We expect that the BETER project will improve healthy life expectancy of HL survivors. Evaluation of follow-up care will lead to a more evidence-based follow-up program.
Rational design of cancer gene panels with OncoPaD
Authors: Carlota Rubio-Perez, Jordi Deu-Pons, David Tamborero, Nuria Lopez-Bigas, Abel Gonzalez-Perez
Journal: Genome Medicine (2016)

Profiling the somatic mutations of genes which may inform about tumor evolution, prognostics and treatment is becoming a standard tool in clinical oncology. Commercially available cancer gene panels rely on manually gathered cancer-related genes, in a "one-size-fits-many" solution. The design of new panels requires laborious search of literature and cancer genomics resources, with their performance on cohorts of patients difficult to estimate. We present OncoPaD, to our knowledge the first tool aimed at the rational design of cancer gene panels. OncoPaD estimates the cost-effectiveness of the designed panel on a cohort of tumors and provides reports on the importance of individual mutations for tumorigenesis or therapy. With a friendly interface and intuitive input, OncoPaD suggests researchers relevant sets of genes to be included in the panel, because prior knowledge or analyses indicate that their mutations either drive tumorigenesis or function as biomarkers of drug response. OncoPaD also provides reports on the importance of individual mutations for tumorigenesis or therapy that support the interpretation of the results obtained with the designed panel. We demonstrate in silico that OncoPaD designed panels are more cost-effective—i.e. detect a maximum fraction of tumors in the cohort by sequencing a minimum quantity of DNA—than available panels. With its unique features, OncoPaD will help clinicians and researchers design tailored next-generating sequencing (NGS) panels to detect circulating tumor DNA or biopsy specimens, thereby facilitating early and accurate detection of tumors, genomics informed therapeutic decisions, patient follow-up and timely identification of resistance mechanisms to targeted agents. OncoPaD may be accessed through http://www.intogen.org/oncopad.
Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma and Renal Impairment: Analysis of Patients from the Phase 3b Stratus Trial (MM-010)
Authors: Katja Weisel, Meletios A. Dimopoulos, Michele Cavo, Enrique M. Ocio, Antonio Palumbo, Paolo Corradini, Michel Delforge, Albert Oriol, Harmut Goldschmidt, Concetta Conticello, Angelo Vacca, Markus Hansson, Neil Miller, Teresa Peluso, Lars Sternas, Mohamed H. Zaki, Philippe Moreau
Journal: Blood (2014)
Role Of Allogeneic Transplant In Poor Risk CLL Patients: A Long-Term Monocentric Experience In 39 Patients
Authors: Therese Aurran-Schleinitz, Anne Wanquet, Sabine Furst, Benjamin Esterni, Reda Bouabdallah, Diane Coso, Christine Arnoulet, Pharm. D., Jean El Cheikh, Catherine Faucher, Luca Castagna, Christian Chabannon, Didier Blaise
Journal: Blood (2013)
Cytokines as Potential Biomarkers of Parkinson Disease
Authors: Roy N. Alcalay
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Autologous Hematopoietic Stem Cell Transplantation for Type I Diabetes Mellitus.
Authors: Julio C. Voltarelli, Carlos E.B. Couri, Maria-Carolina B. Oliveira, Ana-Beatriz P.L. Stracieri, Daniela A. Moraes, Dannielle F. Godoi, Marina A. Coutinho, Kelen C.R. Malmegrim, Maria-Cristina Foss-Freitas, Milton C. Foss, Belinda P. Simoes, Elizabeth C. Squiers, Richard K. Burt
Journal: Blood (2004)
Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline <i>POLE</i> Deficiency Treated with Checkpoint Blockade Immunotherapy
Authors: Tanner M. Johanns, Christopher A. Miller, Ian G. Dorward, Christina Tsien, Edward Chang, Arie Perry, Ravindra Uppaluri, Cole Ferguson, Robert E. Schmidt, Sonika Dahiya, George Ansstas, Elaine R. Mardis, Gavin P. Dunn
Journal: Cancer Discovery (2016)

We present the case of a patient with a left frontal glioblastoma with primitive neuroectodermal tumor features and hypermutated genotype in the setting of a POLE germline alteration. During standard-of-care chemoradiation, the patient developed a cervical spine metastasis and was subsequently treated with pembrolizumab. Shortly thereafter, the patient developed an additional metastatic spinal lesion. Using whole-exome DNA sequencing and clonal analysis, we report changes in the subclonal architecture throughout treatment. Furthermore, a persistently high neoantigen load was observed within all tumors. Interestingly, following initiation of pembrolizumab, brisk lymphocyte infiltration was observed in the subsequently resected metastatic spinal lesion and an objective radiographic response was noted in a progressive intracranial lesion, suggestive of active central nervous system (CNS) immunosurveillance following checkpoint blockade therapy.It is unclear whether hypermutated glioblastomas are susceptible to checkpoint blockade in adults. Herein, we provide proof of principle that glioblastomas with DNA-repair defects treated with checkpoint blockade may result in CNS immune activation, leading to clinically and immunologically significant responses. These patients may represent a genomically stratified group for whom immunotherapy could be considered. Cancer Discov; 6(11); 1230-6. ©2016 AACR.See related commentary by Snyder and Wolchok, p. 1210This article is highlighted in the In This Issue feature, p. 1197.
Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma
Authors: E Malek, M A Y Abdel-Malek, S Jagannathan, N Vad, R Karns, A G Jegga, A Broyl, M van Duin, P Sonneveld, F Cottini, K C Anderson, J J Driscoll
Journal: Leukemia (2016)

While clinical benefit of the proteasome inhibitor (PI) bortezomib (BTZ) for multiple myeloma (MM) patients remains unchallenged, dose-limiting toxicities and drug resistance limit the long-term utility. The E3 ubiquitin ligase Skp1–Cullin-1–Skp2 (SCFSkp2) promotes proteasomal degradation of the cell cycle inhibitor p27 to enhance tumor growth. Increased SKP2 expression and reduced p27 levels are frequent in human cancers and are associated with therapeutic resistance. SCFSkp2 activity is increased by the Cullin-1-binding protein Commd1 and the Skp2-binding protein Cks1B. Here we observed higher CUL1, COMMD1 and SKP2 mRNA levels in CD138+ cells isolated from BTZ-resistant MM patients. Higher CUL1, COMMD1, SKP2 and CKS1B mRNA levels in patient CD138+ cells correlated with decreased progression-free and overall survival. Genetic knockdown of CUL1, COMMD1 or SKP2 disrupted the SCFSkp2 complex, stabilized p27 and increased the number of annexin-V-positive cells after BTZ treatment. Chemical library screens identified a novel compound, designated DT204, that reduced Skp2 binding to Cullin-1 and Commd1, and synergistically enhanced BTZ-induced apoptosis. DT204 co-treatment with BTZ overcame drug resistance and reduced the in vivo growth of myeloma tumors in murine models with survival benefit. Taken together, the results provide proof of concept for rationally designed drug combinations that incorporate SCFSkp2 inhibitors to treat BTZ resistant disease.
Pegylated Liposomal Doxorubicin (Doxil®), Dexamethasone and Low Dose Thalidomide (DDt) as Therapy for Newly Diagnosed Multiple Myeloma.
Authors: Delva Deauna-Limayo, Omar S. Aljitawi, Mathew Mayo, David C. Bodensteiner, Siddhartha Ganguly, Barry S. Skikne, Kambhampati Suman
Journal: Blood (2005)
JAK2V617F-Positive Patients with Essential Thrombocythemia or Early Primary Myelofibrosis: The Impact of Histological Diagnosis on Outcome
Authors: Nicola Polverelli, Roberto Latagliata, Giuseppe A. Palumbo, Alessia Tieghi, Margherita Perricone, Massimo Breccia, Lucia Catani, Francesco Merli, Emanuela Ottaviani, Giuliana Alimena, Giovanni Martinelli, Michele Cavo, Nicola Vianelli, Francesca Palandri
Journal: Blood (2015)
Comparison Of Ultrasound Versus Magnetic Resonance Venography For Diagnosis Of Catheter-Related Thrombosis In Children: A Multicenter Multinational Study
Authors: Christoph Male, Donald L Yee, Christian Loewe, Rajesh Krishnamurthy, Elizabeth Chalmers, Jane Newburger, Luz-Margarita Ramirez, Ronald Portman, Lesley G Mitchell
Journal: Blood (2013)
A new subtype of pre-B-ALL with t(5;12)(q31q33;p12), molecularly and cytogenetically distinct from t(5;12) in CMML
Authors: Iwona Wlodarska, A Aventin, J Ingles-Esteve, D Falzetti, A Criel, Jean-Jacques Cassiman, Christina Mecucci, Herman Van den Berghe, Peter Marynen
Journal: Blood (1996)
Vinorelbine (V) in pemetrexed-pretreated patients (PTS) with malignant pleural mesothelioma (MPM).
Authors: E. Lorenzi, L. Gianoncelli, P. Zucali, G. Ceresoli, F. De Vincenzo, M. Simonelli, C. Ripa, L. Giordano, A. Santoro
Journal: Journal of Clinical Oncology (2010)

7041 Background: Pemetrexed-platinum therapy is the standard of care in the first-line treatment of MPM. The role of second-line therapy is currently undefined. V has shown activity in MPM. The aim of this study was to retrospectively evaluate the activity and toxicity of V in a series of pts previously treated with first-line pemetrexed-based chemotherapy. Methods: V 25 mg/m2 was administered intravenously on days 1,8q21 either as second-line (2L) or further-line (> 2L) therapy. Treatment was repeated for 6 cycles or until progression or unacceptable toxicity. Results: 43 pts were enrolled (2L: 18 pts; > 2L: 25 pts). Median age was 67 (range 43-82). EORTC prognostic score was good in 19 pts and poor in 24 pts. Partial response was observed in 4 (9.3%) pts, stable disease in 12 (27.9%). Disease control rate (DCR) was 37.2%. Median progression-free survival (PFS) was 2.1 months (mo) (0.6-10 mo); median overall survival (OS) was 5.2 mo (0.8-40.3 mo). Pts with a DC achieved a longer PFS (5.2 vs 1.4 mo; p < 0.001), and a longer OS (8.3 vs 3.2 mo; p.017). Pts with a good EORTC score showed an higher DCR (66.7% vs 28.6%; p.023), a longer PFS (3.2 vs 1.5 mo; p.004), and a longer OS (12.5 vs 2.9 mo; p < 0.001). The prognostic role of the EORTC score was confirmed in a multivariate analysis for OS (HR 5.9; CI95% 2.1-16.9; p < 0.001). No difference was observed in terms of DCR, PFS, and OS stratifying for the line of therapy and the response to first line. Grade 3/4 haematological toxicity: neutropenia in 5 (11.6%) pts, without febrile neutropenia. Non-haematological toxicity: grade 2 fatigue in 11 (25.5%) pts and constipation in 4 (9.3%). Conclusions: V was moderately active, with an acceptable toxicity profile, in pemetrexed-pretreated MPM pts, particularly with a good EORTC score. The role of second-line therapy in MPM remains to be evaluated in prospective trials on large series of pts. No significant financial relationships to disclose.